Compare C3.ai Inc (AI) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
C3.ai Inc vs Enveric Biosciences Inc — how do they compare? C3.ai Inc trades at $8.83 (market cap $1.39B), while Enveric Biosciences Inc trades at $1.42 (market cap $5.84M). The key difference: C3.ai Inc is far larger — about 238× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.
| AI | ENVB | |
|---|---|---|
Market Cap | $1.39B | $5.84M |
Sector | Technology | Health |
52-Week High | $29.16 | $17.40 |
52-Week Low | $7.76 | $1.28 |
Enterprise Value | $818.29M | $932.52K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai trades at $8.93, down 1.43% with bearish technical signals. The company shows revenue growth to $389M in 2025 but continues significant losses with -$289M net income. Analyst sentiment is mixed with 21% buy ratings and consensus target of $10.20. Recent developments include board member Jim Hagemann Snabe's appointment as European Commission Special Envoy for Industrial AI.
While revenue growth presents opportunity, persistent losses and negative cash flow pose substantial risk. The stock faces headwinds from unprofitability despite beating some earnings estimates. Upside potential exists if the company can accelerate path to profitability amid growing enterprise AI adoption.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
